Baricitinib for Depression

(JAK DC in Play Trial)

This trial aims to explore how inflammation might affect depression and cognitive issues, specifically in former football players. Participants will take baricitinib, a medication that reduces inflammation, to determine if it alleviates depressive symptoms. The trial seeks men who have played organized football for over ten years and are experiencing symptoms of depression.

As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

You may need to stop taking certain medications. Participants must be off all antidepressant or other psychotropic therapy (like mood stabilizers and antipsychotics) for at least 4 weeks before the study starts, or be on a stable regimen for at least 4 weeks with no planned changes.

Research shows that baricitinib has been tested for safety in various conditions. Studies on COVID-19 patients found no major safety issues with baricitinib use for up to 14 days. Additionally, a large safety review for rheumatoid arthritis showed similar safe results, with a side effect rate of 22.6 per 100 patient years, considered low.

Baricitinib is unique because it targets the Janus kinase (JAK) pathway, which is different from the usual neurotransmitter-focused approach in depression treatments like SSRIs and SNRIs. Most standard treatments for depression, such as fluoxetine or sertraline, work by altering serotonin levels in the brain. However, baricitinib's novel mechanism of action could offer new insights and potential benefits for those who don't respond well to traditional therapies. Researchers are excited about the possibility of baricitinib providing relief for patients with treatment-resistant depression, expanding the current landscape of depression management.

Research has shown that baricitinib, a medication that reduces inflammation, might help treat depression. Some studies found it can improve depression symptoms, especially when inflammation levels are high. In trials, baricitinib reduced symptoms more effectively than a placebo. It blocks certain proteins involved in inflammation, which is thought to play a role in depression. While researchers continue to collect more data, early results are promising for people with depression that hasn't responded to other treatments. Participants in this trial will receive baricitinib, starting with a dose of 2 mg daily, with the possibility of increasing to 4 mg daily if there is no clinical response at 4 weeks.³⁶⁷⁸⁹